Tetragon Partners GP Ltd
GRAND CAYMAN, E9 · CIK 1515070 · 13F filing filed 2026-08-13
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
Options: 7 call positions ($20.7m notional), 0 put positions (— notional) – listed below, not included above.
This report includes the holdings of 3 other managers that share the investment decisions:
- Tetragon Partners L.P. – reports through this filing
- Tetragon Partners UK LLP – reports through this filing
- Tetragon Partners US LP – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| UIPATH INC PATH | $336.4m54.76% | Added +5.7m |
| KOLIBRI GLOBAL ENERGY INC KGEI | $33.8m5.51% | Unchanged |
| AUTOLUS THERAPEUTICS PLC AUTL | $15.2m2.47% | Unchanged |
| LYFT INC LYFT | $14.6m2.38% | Unchanged |
| DEFINIUM THERAPEUTICS INC DFTX | $13.5m2.20% | Added +87.0k |
| WORKIVA INC WK | $12.1m1.97% | Unchanged |
| SPRINKLR INC CXM | $11.4m1.85% | Unchanged |
| MBX BIOSCIENCES INC MBX | $11.2m1.83% | Added +58.1k |
| ALKAMI TECHNOLOGY INC ALKT | $10.9m1.77% | New |
| CELLDEX THERAPEUTICS INC NEW CLDX | $10.8m1.76% | Reduced -21.9k |
| RELAY THERAPEUTICS INC RLAY | $10.7m1.74% | Added +388.8k |
| ARROWHEAD PHARMACEUTICALS IN ARWR | $10.6m1.73% | Added +3.3k |
| PHARVARIS N V PHVS | $10.2m1.66% | Added +74.0k |
| ALKERMES PLC ALKS | $10.0m1.62% | Added +30.2k |
| IMMUNOVANT INC IMVT | $9.9m1.61% | Added +37.4k |
| SILENCE THERAPEUTICS PLC SLN | $8.4m1.37% | Added +134.1k |
| DYNE THERAPEUTICS INC DYN | $7.9m1.29% | Added +98.5k |
| IONIS PHARMACEUTICALS INC IONS | $7.7m1.25% | Added +55.4k |
| AGIOS PHARMACEUTICALS INC AGIO | $7.6m1.24% | Added +40.7k |
| HARMONY BIOSCIENCES HLDGS IN HRMY | $7.3m1.19% | Added +81.7k |
| KRYSTAL BIOTECH INC KRYS | $7.3m1.19% | Unchanged |
| ANNEXON INC ANNX | $7.1m1.15% | Reduced -50.0k |
| CELCUITY INC CELC | $6.7m1.09% | New |
| WARNER BROS DISCOVERY INC WBD | $6.7m1.08% | Reduced -673.7k |
| NEKTAR THERAPEUTICS NKTR | $6.1m0.99% | Reduced -16.0k |
| AMYLYX PHARMACEUTICALS INC AMLX | $5.4m0.87% | Reduced -20.0k |
| ACADIA PHARMACEUTICALS INC ACAD | $4.2m0.69% | Added +23.3k |
| CUE BIOPHARMA INC CUE | $3.0m0.48% | New |
| SNOWFLAKE INC SNOW | $2.5m0.41% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $2.1m0.34% | New |
| TECTONIC THERAPEUTIC INC TECX | $1.6m0.26% | Added +8.9k |
| MONTE ROSA THERAPEUTICS INC GLUE | $1.4m0.22% | New |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| PRAXIS PRECISION MEDICINES I PRAX | $5.1m16.0k shares |
| SOLENO THERAPEUTICS INC SLNO | $3.4m102.1k shares |
| AXSOME THERAPEUTICS INC AXSM | $3.4m20.1k shares |
| MAPLIGHT THERAPEUTICS INC MPLT | $2.3m112.1k shares |
| AARDVARK THERAPEUTICS INC AARD | $1.2m316.6k shares |
| ULTRAGENYX PHARMACEUTICAL IN RARE | $827.0k39.5k shares |
| KARYOPHARM THERAPEUTICS INC KPTI | $295.1k53.0k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| AXSOME THERAPEUTICS INC AXSM · Call | $8.6m35.0k shares | Unchanged |
| ULTRAGENYX PHARMACEUTICAL IN RARE · Call | $3.3m100.0k shares | New |
| SILENCE THERAPEUTICS PLC SLN · Call | $3.3m300.0k shares | New |
| KARYOPHARM THERAPEUTICS INC KPTI · Call | $2.4m250.3k shares | Added |
| AGIOS PHARMACEUTICALS INC AGIO · Call | $1.9m50.0k shares | New |
| TENAX THERAPEUTICS INC TENX · Call | $1.1m75.1k shares | New |
| AMYLYX PHARMACEUTICALS INC AMLX · Call | $152.7k8.5k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| KOLIBRI GLOBAL ENERGY INC KGEI · 13G · filed 2025-09-10 | 19.8%≈ $35.2m |
| UIPATH INC PATH · 13G · filed 2026-07-15 | 6.8%≈ $336.4m |